These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29601121)

  • 1. PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
    Fang H; Jin J; Huang D; Yang F; Guan X
    Cancer Sci; 2018 Jun; 109(6):1949-1957. PubMed ID: 29601121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
    Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway.
    Jin J; Sun Z; Yang F; Tang L; Chen W; Guan X
    Arch Biochem Biophys; 2018 May; 645():54-60. PubMed ID: 29550144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
    Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
    Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
    Gardaneh M; Shojaei S; Kaviani A; Behnam B
    Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
    Han S; Meng Y; Tong Q; Li G; Zhang X; Chen Y; Hu S; Zheng L; Tan W; Li H; Chen Y; Zhang G; Li B; Guo Y
    MAbs; 2014; 6(2):403-8. PubMed ID: 24492292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer.
    Wang L; Yu X; Dong J; Meng Y; Yang Y; Wang H; Wang C; Zhang Y; Zhao Y; Zhao J; Wang H; Lu C; Li B
    Biochem Biophys Res Commun; 2016 Oct; 479(3):563-570. PubMed ID: 27666484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
    Chen Y; Alvarez EA; Azzam D; Wander SA; Guggisberg N; Jordà M; Ju Z; Hennessy BT; Slingerland JM
    Breast Cancer Res Treat; 2011 Jul; 128(1):69-78. PubMed ID: 20669046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
    Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
    PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
    Cavalloni G; Peraldo-Neia C; Sarotto I; Gammaitoni L; Migliardi G; Soster M; Marchiò S; Aglietta M; Leone F
    Mol Cancer Ther; 2012 Jul; 11(7):1528-38. PubMed ID: 22452946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.
    Zazo S; González-Alonso P; Martín-Aparicio E; Chamizo C; Luque M; Sanz-Álvarez M; Mínguez P; Gómez-López G; Cristóbal I; Caramés C; García-Foncillas J; Eroles P; Lluch A; Arpí O; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
    Mol Cancer Ther; 2020 Aug; 19(8):1696-1707. PubMed ID: 32404410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
    Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
    Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
    Simpkins F; Hevia-Paez P; Sun J; Ullmer W; Gilbert CA; da Silva T; Pedram A; Levin ER; Reis IM; Rabinovich B; Azzam D; Xu XX; Ince TA; Yang JY; Verhaak RG; Lu Y; Mills GB; Slingerland JM
    Clin Cancer Res; 2012 Nov; 18(21):5911-23. PubMed ID: 22896656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.
    Chua KN; Kong LR; Sim WJ; Ng HC; Ong WR; Thiery JP; Huynh H; Goh BC
    Oncotarget; 2015 Oct; 6(30):29991-30005. PubMed ID: 26358373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
    Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment of Src inhibitor Saracatinib with GMI, a Ganoderma microsporum immunomodulatory protein, induce synthetic lethality via autophagy and apoptosis in lung cancer cells.
    Chiu LY; Hsin IL; Tsai JN; Chen CJ; Ou CC; Wu WJ; Sheu GT; Ko JL
    J Cell Physiol; 2021 Feb; 236(2):1148-1157. PubMed ID: 32686156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial cells promote triple-negative breast cancer cell metastasis
    Zhang W; Xu J; Fang H; Tang L; Chen W; Sun Q; Zhang Q; Yang F; Sun Z; Cao L; Wang Y; Guan X
    FASEB J; 2018 Jan; 32(1):276-288. PubMed ID: 28899878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.